Close Menu

NEW YORK (GenomeWeb) – Investment firm Piper Jaffray last night upgraded its rating on Myriad Genetics' stock to overweight and increased its price target on the shares to $53, citing commercial payors' growing willingness to cover several tests in its portfolio.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.